Abstract
Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged in many countries. To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants, we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG + ) memory B cells. Anti-spike antibody induction is robust in these patients, and five mAbs have potent neutralizing activities. The efficacy of most neutralizing mAbs and convalescent plasma samples is maintained against B.1.1.7 and mink cluster 5 variants but is significantly decreased against variants B.1.351 from South Africa and P.1 from Brazil. However, mAbs with a high affinity for the receptor-binding domain remain effective against these neutralization-resistant variants. Rapid spread of these variants significantly impacts antibody-based therapies and vaccine strategies against SARS-CoV-2.
Keywords: COVID-19; SARS-CoV-2; mAb; neutralizing antibody; variant.
【저자키워드】 COVID-19, neutralizing antibody, SARS-CoV-2, variant, mAb, 【초록키워드】 coronavirus disease, severe acute respiratory syndrome coronavirus 2, convalescent plasma, neutralizing antibody, Brazil, IgG, Coronavirus disease 2019, Efficacy, Vaccine, coronavirus, Mutation, Neutralizing antibodies, antibody, B.1.351, variant, SARS-CoV-2 variant, Infection, memory B cells, severe acute respiratory syndrome Coronavirus, variants, Spike protein, Spread, Convalescent patients, South Africa, Receptor-binding domain, Immunoglobulin, SARS-CoV-2 variants, B.1.1.7, P.1, Impact, Rapid, Cluster, Neutralizing, respiratory, patients, single-cell, mAbs, Anti-spike, neutralizing monoclonal antibodies, convalescent patient, neutralizing monoclonal antibody, antibody-based therapies, anti-spike antibody, therapeutic option, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, high affinity, anti-spike MAbs, neutralizing activities, convalescent plasma samples, FIVE, effective, antibody-based therapy, robust, evaluate, caused, significantly, the spike protein, the receptor-binding domain, convalescent COVID-19 patient, 【제목키워드】 antibody, neutralization, SARS-CoV-2 variant, resistance, convalescent patient, with COVID-19,